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Abstract
The purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological
lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological
angiogenesis at least by controlling extracellular proteolysis and by regulating endothelial cell survival and migration.
Protease system’s role in lymphangiogenesis is unknown yet. Thus, based on its important pro-angiogenic effect, we
hypothesized that PAI-1 may regulate lymphangiogenesis associated at least with metastatic dissemination of cancer cells.
To address this issue, we studied the impact of PAI-1 deficiency in various murine models of tumoral lymphangiogenesis.
Wild-type PAI-1 proficient mice were used as controls. We provide for the first time evidence that PAI-1 is dispensable for
tumoral lymphangiogenesis associated with breast cancers either induced by mammary carcinoma cell injection or
spontaneously appearing in transgenic mice expressing the polyomavirus middle T antigen (PymT) under the control of a
mouse mammary tumor virus long-terminal repeat promoter (MMTV-LTR). We also investigated inflammation-related
lymphatic vessel recruitment by using two inflammatory models. PAI-1 deficiency did neither affect the development of
lymphangioma nor burn-induced corneal lymphangiogenesis. These novel data suggest that vascular remodelling
associated with lymphangiogenesis and angiogenesis involve different molecular determinants. PAI-1 does not appear as a
potential therapeutic target to counteract pathological lymphangiogenesis.
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Introduction
The lymphatic network is composed of blind-ended lymphatic
vessels that regulate tissue homeostasis, the afferent immune
response and fat transport. After collecting extravasated protein-
rich fluid and lymphocytes from the extracellular space or
triglycerides from the gut, lymphatic capillaries transport them
back to the blood circulation through larger vessels and lymph
nodes [1]. Tumoral cell metastasis may occur by invading either
the blood circulation or the lymphatic vascular system. The
increased permeability and the absence of basement membrane of
lymphatic vessels compared to blood vessels facilitate the
intravasation of tumor cells into the lymphatic system. Therefore,
lymphatic vessels offer an easy way for cancer cells to disseminate
and form metastasis into the lymph nodes before reaching the
blood circulation. This is supported by the clinical investigation of
the sentinel lymph node while searching for cancer dissemination
in patients [2]. Moreover, the lymphatic system is involved in
chronic inflammatory diseases and in transplant rejection (renal
and corneal graft rejection) [3]. Therefore, a better understanding
of the molecular and cellular basis of lymphatic abnormalities
associated with cancers and inflammation is essential for the
development of novel therapeutic strategies.
Components of the plasminogen activation system are involved
in several physiological and pathological processes associated with
important tissue remodelling [4]. This proteolytic system is
composed of serine proteases including tissue-type plasminogen
activator (tPA), urokinase-type plasminogen activator (uPA), uPA
receptor (uPAR) and the plasminogen activator inhibitors (PAI),
the main one being PAI-1. The contribution of these proteins in
cancer progression relies on their capacity to control various
biological processes such as (i) cell proliferation [5]; (ii) cell invasion
through plasmin-mediated extracellular matrix degradation [6];
(iii) cell adhesion and migration through the interaction of uPA/
uPAR/PAI-1 complex with vitronectin and integrins [7]; and (iv)
cell apoptosis through the control of pro-apoptotic factor release
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9653[8]. PAI-1 is now recognized as an essential factor of the host
microenvironment that promotes tumor growth, vessel recruit-
ment [9–14] and dissemination of tumoral cells to distant organs
[15,16]. The effect of PAI-1 depends on its concentration, being
pro-angiogenic at physiological concentration and anti-angiogenic
at pharmacological concentrations [14,17–19] These experimental
observations confirm the positive correlation existing between
PAI-1 blood levels, the rate of metastasis and the poor prognostic
of patient with different types of cancers (for review: [5]). The
essential role of PAI-1 in angiogenesis was also demonstrated in a
laser-induced model of choroidal angiogenesis that mimics the
age-related macular degeneration extending its function to ocular
diseases [11,14].
Based on its pivotal role during tumoral angiogenesis, a
contribution of PAI-1 in lymphangiogenesis is anticipated, but
not documented. In the present study, to address this issue, we
applied different models of tumoral and inflammation-induced
lymphangiogenesis into PAI-1 deficient mice having different
genetic backgrounds.
Methods
Transgenic Modified Mice
Homozygous PAI-1 deficient mice (PAI-1
2/2) and their
corresponding wild type mice (PAI-1 WT) were those previously
used for angiogenesis studies with a mixed genetic background of
87% C57BL/6 and 13% 129SV/SL strain [8,17,20]. Their
corresponding immunodeficient mice were generated in a RAG-
1
2/2 background and genotyped by PAI-1 and PGKPA gene
annealing as previously described [10,20]. Heterozygous FVB/N-
PyMT male mice obtained from Finsen Laboratory (Copenhagen,
Denmark) were mated with homozygous PAI-1
2/2 and PAI-1
WT female mice, which were backcrossed for eight generations
into the FVB/N strain [21]. Mouse experimentation was done in
accordance to the guidelines of the University of Lie `ge regarding
the care and use of laboratory animals.
Cell Lines
The human MCF-7 breast carcinoma cell line transfected either
with human VEGF-C mature form cDNA (MCF-7/VEGF-C) or
with control cDNA (MCF-7/EB57II) were obtained from Kari
Alitalo (University of Helsinki, Finland) [22]. Cells were routinely
cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA)
supplemented with GlutaMAX, 25 mM Hepes, penicillin
(100 U/ml), streptomycin (100 mg/ml), hygromycin (150 mg/
ml) and 10% fetal bovine serum (Gibco, Grand Island, NY).
Amplification of VEGF-C cDNAs was carried out by polymerase
chain reaction using the reverse primers: TTG-TTC-GCT-GCC-
TGA-CAC-TG and the forward primers: CTC-TCT-CTC-AAG-
GCC-CCA-AA. The PCR condition was 94uC for 0.15 min, 55uC
for 0.2 min, and 72uC for 0.2 min, for 30 cycles. Human VEGF-C
ELISA (R&D Systems, Minneapolis, MN) was performed on
medium conditioned by cells according manufacture’s instructions.
Mammary Orthotopic Transplantation
Subconfluent MCF7 cultures were harvested by trypsinization,
washed twice and resuspended in serum-free medium. Cells
(2.5610
6/50 ml) were bilaterally inoculated into the fat pads of the
fifth mammary glands (mfp) of 8- to 12-week-PAI-1
2/2 and, -WT
RAG-1
2/2 female mice. Mice were supplemented with a
subcutaneous 60-days slow-release pellet containing 0.72 mg of
17ß-estradiol (Innovative Research of America, Toledo, OH).
Tumor growth was measured with a calliper and the volume was
calculated according to the formula V=(p/6)(d1Xd2)
3/2 [23].
After 16 weeks, mice were killed and tumors, lungs and lymph
nodes were collected. All the samples were formalin fixed and
paraffin embedded. The tumor incidence is defined as the
percentage of animals bearing a palpable tumor. Two separate
sets of experiments with similar results were performed with each
time at least 8 to 11 mice per experimental group; presented data
are combined results (34–38 injected mammary fat pads (mfp) per
condition).
Tumor Processing in PyMT Mice
Female mice heterozygous for the PyMT transgene and
homozygous for the wild type or mutated PAI-1 gene were used
in these studies. After 8, 11 or 14 weeks, mice were killed and
tumors, lungs and lymph nodes were collected. Tumors were
weighted before formalin fixation and paraffin embedding. To
avoid any variance from the fat pad localisation (peritoneal-
localised tumors being bigger than those developed in the thoracic
cavity), all the individual tumor weights were summed to give the
total tumor weight of each mice. The number of mice sacrified per
genotype was: 19 for PyMT PAI-1 WT mice and 23 for PyMT
PAI-1
2/2 mice sacrified at 14 weeks; 17 for PyMT PAI-1 WT
mice and 9 for PyMT PAI-1
2/2 mice sacrified at 11 weeks and 12
for PyMT PAI-1 WT mice, and 7 for PyMT PAI-1
2/2 sacrified at
8 weeks.
Lymphangioma
Lymphatic endothelial hyperplasia (lymphangioma) formation
was induced by two intraperitoneal injections of incomplete
Freund’s adjuvant [24]. For ethical purposes, buprenorphine
hydrochloride injections (0.05 mg/kg, TEMGESICH, Reckitt
Benckiser, UK) were administered every 12 h during the first
5 days 1 h before and after adjuvant injections. After 4 weeks,
mice (n=6) were killed and lymphangioma masses appearing at
the surface of diaphragm were photographed for quantification
using the ImageJ 1.40 g software (NIH). The lymphangioma
development was determined by reporting the lymphangioma
surface on the total organ area. The lymphatic origin of tumors
was assessed by positivity for LYVE-1 as described above. Sirius
Red staining was obtained by incubating the deparaffinised and
ionised slides with 0.1% Sirius Red (Polyscience, Warrington,
PA)/picric acid (1.15 g/100 ml). Slides were then rapidly
incubated in 90% alcohol and in xylene before being mounted
with Eukitt medium.
Immunohistochemistry on Slides and Metastasis
Detection
All reagents and procedure are summarized in Table 1. In brief,
after deparaffination and rehydration, immunostainings were
performed on 6 mm slides by first unmasking antigens and
subsequently blocking endogenous peroxidases by 3% H2O2/
H2O for 20 min. Nonspecific binding was prevented by a specific
treatment before the incubation with primary and secondary (if
needed) antibodies followed by incubation with a streptavidin/
HRP complex (DAKO, Glostrup, Denmark, 1/500) at room
temperature (RT) for 30 min. Slides were stained with 3-
39diaminobenzidine hydrochloride (DAKO, Glostrup, Denmark)
for 3 min to 10 min, counterstained with hematoxylin and
mounted with Eukitt medium for microscope observation.
Omission of the first antibody served as negative control.
Metastases in the lymph nodes and in lungs of mice bearing
MCF7 tumors or PyMT mice were detected by immunostaining
(Table 1). Results are expressed as the percentage of animals
presenting at least one metastatic nodule.
PAI-1 in Lymphangiogenesis
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Lymphangioma
ImageJ software (NIH) was used to first manually delineate the
immunolabelled vessels. We binarized images and optimized the
threshold to highlight the vessels. For mammary tumors, the
following parameters were determined on the whole tumor
section: the relative vascular area (lymphatic vessel area reported
to the total area of the tumor (mm
2/mm
2)), the number of sections
of lymphatic vessels (reported to the total area of the tumor (1/
mm
2)) and the mean vessel area (lymphatic vessel area divided by
the number of vessels (mm
2)). For lymphangiomas, due to the
variation in lymphangioma width associated with different fibrotic
reaction, vessel quantifications are expressed by total vessel area
(mm
2) (at least 3 images were analyzed per sample (n=6)).
Corneal Assay
Corneal lymphangiogenesis was induced by thermal cauteriza-
tion of the central cornea by using an ophthalmic cautery
(OPTEMP II V, Alcon Surgial, Fort Worth, USA). Seven days
later, mice were sacrificed, eyes were removed and corneas were flat
mounted (n=5, one flat mount per mice). Whole corneas were
stained after fixation in ethanol 70%. Cornea whole mounts were
blocked in 1,5% BSA-3% Gloria milk for 1 h at RT and incubated
overnight with rabbit anti-LYVE-1 (1/600, a kind gift from Dr. K.
Alitalo, Finland). After four 10 min washes with PBS, corneas were
incubated with the FITC-coupled swine anti-rabbit Ig (1/40;
DAKO, Glostrup, Denmark) for 60 min at RT and whole-mounted
on a microscope slide with Vectashield-DAPI mounting medium
(Vector Laboratories, Burlingame, CA). The area covered by
immunostained lymphatic vessels was determined and normalized
to the total corneal area. We also measured the length densities
defined as the total area occupied by lymphatic network and the
cumulative length of vessels. For both parameters, results are
expressed percorneal areaunit (mm
2). As themechanism ofvascular
growth is sprouting, its extent can be detected by the increase of
vessel network extremities, which corresponds to the number of
smallest vessels (so-called first order vessels in the centripetal
ordering method) [25]. To achieve this, we determined the end-
point density defined as the vessel network extremity number per
corneal area unit. The branching density (defined as the vessel
branching number per corneal area unit) was also measured to
evaluate the degree of the vessel tree complexity [26].
Statistical Analysis
Statistical analyses were performed using GraphPad PRISM 4
software. Incidences were evaluated as contingency table by
Fisher’s exact test. Other variables were tested by a one-way
ANOVA (Kruskal-Wallis test) followed by the Mann Whitney test
in order to avoid multiplicity. These tests were also used to
determine significance in the morphometric analyses. Results are
expressed 6 S.E.M. Differences were considered statistically
significant for P values less than or equal to 0.05.
Results
PAI-1 Is Dispensable for Lymphangiogenesis in an
Experimental Model of Breast Cancer
To test the impact of PAI-1 on lymphatic vessel recruitment in
tumors, VEGF-C-overexpressing MCF7 cellsor controlMCF7 cells
were bilaterally injected into the fifth mammary fat pads (mfp) of
immunodeficient RAG-1
2/2 mice that are deficient in PAI-1 (PAI-
1
2/2) or not (PAI-1 WT). We checked the production of VEGF-C
by the tumor cells in culture by RT-PCR (Fig. 1A) and in
supernatants by ELISA (data not shown). Mice were supplemented
Table 1. Antibodies and procedure used for immunochemistry to detect metastasis on lung and lymph node slides, lymphatic
vessels and inflammatory cells on primary tumors/lymphangiomas.
Steps of immunohistochemistry
Antibody used Unmasking Blockage Primary antibodies Secondary antibodies
Detection of MCF7
tumor metastasis in
lymph nodes and lungs.
0.05% H2O2/trypsin,
40 min at 37uC
PBS/bovine serum albumin
0% (Fraction V, Acros
Organics1, NJ), 1 hour
Mouse anti-human pS2
protein (1/50, 1h30 at RT)
(DAKO, Glostrup, Denmark)
Goat anti-mouse Envision/HRP
(30 min at RT) (DAKO, Glostrup,
Denmark)
Detection of MCF7
tumor metastasis in
lymph nodes.
0.05% H2O2/pronase,
10 min at RT
normal goat serum,
30 min
Rabbit anti-cytokeratin WSS
(Wide Spectrum Screening)
(1/500, 1 h at 37uC) (DAKO,
Glostrup, Denmark)
Goat anti-rabbit/biotine (1/400,
30 min at RT) (DAKO, Glostrup,
Denmark)
Detection of MCF7
tumor metastasis in
lungs.
Target Retrieval Solution
(DAKO, Glostrup, Denmark),
11 min at 126uC
H2O2/Universal Blocking
Reagent (1/10, BioGenex,
San Ramon, USA), 10 min
Rat anti-Ki-67 (1/50, 1 h at
RT), (DAKO, Glostrup,
Denmark)
Rabbit anti-rat/biotine (1/300,
30 podoplaninmin at RT), (DAKO,
Glostrup, Denmark)
Detection of PyMT
tumor metastasis in
lymph nodes.
Citrate buffer (pH 6),
11 min at 126uC
H2O2/Universal Blocking
Reagent (1/10, BioGenex,
San Ramon, USA), 10 min
Rabbit anti-cytokeratin 8
(1/100, 1 h at RT) (Abcam,
Cambridge, PA)
Goat anti-rabbit/biotine (1/400,
30 min at RT) (DAKO, Glostrup,
Denmark)
Detection of
lymphatic vessels
Target Retrieval Solution
(DAKO, Glostrup, Denmark),
11 min at 126uC
PBS/bovine serum albumin
10% (Fraction V, Acros
Organics, NJ), 1 h
Rabbit anti-Lyve-1 (1/1000,
1h30 at RT) (Upstate, Lake
Placid, NY)
Goat anti-rabbit/biotine (1/400,
30 min at RT) (DAKO, Glostrup,
Denmark)
Detection of
lymphatic vessels
Citrate buffer (pH 6),
11 min at 126uC
normal goat serum, 30 min Syrian hamster anti-podo-
planin (1/1000, 1 h at RT)
(Reliatech, Braunschweig,
Germany)
Goat anti-syrian hamster/biotine
podoplanin(1/500, 30 min at RT)
(Jackson ImmunoResearch,
podoplaninBaltimore, US)
Detection of inflam-
matory cells
Citrate buffer (pH 6),
11 min at 126uC
H2O2/Universal Blocking
Reagent (1/10, BioGenex,
San Ramon, USA), 10 min
Mouse anti CD45/biotine
podoplanin(1/500, 1 h at RT)
(Pharmingen, San Diego, USA)
Amplification with biotinylated
tyramide (PerkinElmer, MA, USA)
RT=Room temperature.
doi:10.1371/journal.pone.0009653.t001
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releasing pellets. Two separate sets of experiments with similar
results were performed with at least 8 to 10 mice per experimental
group (34–38 mfp per condition). At week 16, both PAI-1 WT and
PAI-1
2/2 mice implanted with VEGF-C expressing cells showed
higher tumor incidence (P=0.0051, P,0.0001, respectively;
Fig. 1B) and, in PAI-1 WT mice, a tendency to a higher tumor
volume (P=0.1513; Fig. 1C) than mice inoculated with mock
MCF7cells.Itisworth notingthattheeffect ofVEGF-Con tumoral
volume didn’t reached the statistical significance due to the low
number of tumors detected in mice injected with the non-VEGF-C
producing cells (3 out of 38 mfp). Interestingly, PAI-1 deficiency
reduced the incidence of tumors developed both in the presence of
VEGF-C expression (52% of VEGF-C expressing tumors in PAI-1
WT mice versus 22% in PAI-1
2/2 mice) (P,0.0089) and in its
absence (8% of control tumors in PAI-1 WT mice versus 0% in PAI-
1
2/2 mice) (Fig. 1B). When considering the volume of tumors,
differences did not reach statistical differences between PAI-1 WT
and PAI-1
2/2 mice (Fig. 1C).
The metastatic ability of cells was assessed by immunochemical
staining with antibodies raised against pS2 protein and cytokeratin
WSS on lymph node sections or against pS2 protein and Ki-67 on
lung sections. Histological examination in the lung (P=0.2879) or
the lymph nodes (P=0.1037) of mice bearing a VEGF-C
expressing tumor revealed similar metastasis incidence for the
two different groups (PAI-1 WT or PAI-1
2/2 mice) (Fig. 1D, E).
The lymphatic vasculature was next investigated on primary
tumors (Fig. 2A). Through Lyve-1 immunolabeling on tumor
sections, quantification performed by computerized image analysis
led to the determination of 3 different parameters (Fig. 2B, C, D). In
accordance to previous report [23], VEGF-C over-expressing
tumors displayed a higher relative vasculature area than control
tumors. However, the VEGF-C-induced lymphatic vasculature was
similar in PAI-1 WT and PAI-1
2/2 mice (P=0.4048) (Fig. 2B).
Because of the very low number of tumors developed in the absence
ofVEGF-C(3outof38 mfpinPAI-1WTmice and0 outof34 mfp
in PAI-1
2/2 mice), no comparison could be performed between the
two genotypes. This increased lymphatic vessel area observed in the
Figure 1. Tumor development after orthotopic injection of VEGF-C overexpressing MCF7 cells or control MCF7 cells implanted in
the mammary fat pads (mfp) of PAI-1 WT or PAI-1
2/2 mice. (A): RT-PCR analysis of VEGF-C and 28S mRNA expression by MCF7. (B): Tumor
incidence (%) is defined as the percentage of palpable tumor per mfp. (C): Tumor volume was measured as described in Material and Methods. (D):
Representative figure of a typical metastasis in lymph node (left) and lung (right). (E): Percentage of animal bearing at least a tumor nodule
(metastasis% detected in lymph nodes (black boxes) and lungs (white boxes). Number of mfp per condition=34–38. The mice PAI-1 status (WT or 2/
2) and the VEGF-C production (VEGF-C) or not (Ctl) by MCF7 cells are indicated below each graph. Data are 6 S.E.M. Scale bars: 200 mm. ** P#0.01,
*** P#0.001, NS=Non Significant.
doi:10.1371/journal.pone.0009653.g001
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while vessel size was unchanged (Fig. 2D).
PAI-1 Is Dispensable for Lymphangiogenesis and
Metastatic Dissemination in a Spontaneous Model of
Breast Tumors
In order to further analyse the role of PAI-1 in tumor growth
and metastatic dissemination, we used transgenic PyMT mice that
spontaneously develop mammary tumors. PyMT mice were
crossed with PAI-1 WT or PAI-1
2/2 mice in a FVB/N
background. At week 8 or 11, difference was observed neither in
tumor incidence (100%) nor in tumor weight (P=0.8875; Fig. 3A).
A very slight increase of tumor weight was even observed after 14
weeks in PAI-1 KO mice (P=0.0461). Histochemical and
immunochemical analyses detecting cytokeratin 8 and Ki67 did
not reveal any difference in the metastatic dissemination into the
lung or lymph nodes between PyMT PAI-1 WT and PyMT PAI-
1
2/2 mice sacrified after 14 weeks (fig. 3B). Indeed, metastatic
nodules were detected in the lung of 63.1% (12/19) of PyMT PAI-
1 WT mice and 52.2% of PymT PAI-1
2/2 mice (12/23)
(P=0.5421). Similarly, lymph nodes of 73,68% (14/19) of PyMT
PAI-1 WT mice and 47,8% (11/23) of PymT PAI-1
2/2 mice
(P=0.1203) were infiltrated by tumoral cells.
In order to quantify the lymphatic vasculature inside primary
PyMT tumors, a computer-assisted automatic quantification
Figure 2. Analysis of intratumoral lymphatic vessels in tumors induced by orthotopic injection of VEGF-C overexpressing MCF7 or
control MCF7 cells implanted in the mammary fat pads (mfp) of PAI-1 WT or PAI-1
2/2 mice. (A): Representative images of Lyve-1 positive-
vessels at two different magnifications in VEGF-C expressing tumors developed in WT mice (WT) or PAI-1 deficient mice (
2/2), and in control tumors
(Ctl). (B–D): Quantification of lymphatic vessels has been performed by computerized image analysis and led to the determination of three
parameters: 1- relative vascular area (area occupied by intratumoral lymphatic vessels reported to the total tumor surface) (B); 2- number of lymphatic
vessel sections per slide (number of vessels) (C) and; 3- mean lymphatic vessel size (D). The mice PAI-1 status (WT or 2/2) and the VEGF-C production
(VEGF-C) or not (Ctl) by MCF7 cells are indicated below each graph. Data are 6 S.E.M. NS=Non Significant.
doi:10.1371/journal.pone.0009653.g002
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labelling was observed between tumors generated in both
genotypes after 14 weeks (P=0.0945) (Fig. 3C).
PAI-1 Deficiency Does Not Affect Inflammation-Related
Lymphangiogenesis
In order to explore PAI-1 impact on the lymphatic vessel
recruitment in inflammatory conditions, we applied a model of
lymphatic endothelial cell hyperplasia called lymphangioma [24]
to PAI-1 WT (n=6) and PAI-1
2/2 (n=6) mice. After 4 weeks,
mice were sacrified and the lymphangiomas that appeared as
white masses underneath the diaphragm were measured. The
surface of lymphangioma area was reported to the total area of the
organ (percentage of invasion). Macroscopical analyses revealed
that the lymphangioma surface was decreased with PAI-1
deficiency (P,0.01, Fig. 4A). Immunohistochemical analyses of
these lymphangiomas were assessed with Lyve-1 and CD45
antibodies to label lymphatic vessels and inflammatory cells,
respectively. Fibrosis was evaluated through Sirius red staining.
Quantification was performed by a semi-automatic computer-
assisted method. The microscopical analyses of lymphangioma
sections showed that the area covered by lymphatic vessels was
similar in PAI-1
2/2 compared to corresponding wild type mice
(P=0.49, Fig. 4B). However, we pointed out differences in the
lymphatic vessel structure between the experimental groups. The
number of vessels per section was 5465 mm
2 in PAI-1 WT and
3162 mm
2 in PAI-1
2/2 (P=0.0002), and the vessel average
surface was 383643 mm
2 in PAI-1 WT and was 663657 mm
2 in
PAI-1
2/2 (P=0.0003). Thus, vessels in PAI-1
2/2 mice were
fewer but larger leading to an equal vessel area than counterparts.
No difference was detected regarding the surface occupied by
inflammatory cells (P=0.44, Fig. 4C). In sharp contrast, decrease
of red Sirius stained fibrosis was observed in PAI-1
2/2 mice
(P,0.01, Fig. 4D) and could explain the reduction of the
lymphangioma area observed macroscopically in these mutant
mice.
PAI-1 Is Dispensable for Corneal Lymphangiogenesis
We then extended our study to an additional model of
lymphangiogenesis related to inflammation. The corneal assay is
an in vivo model which consists in a neovascularization induced by
burning the central area of mouse cornea [28]. We previously
confirmed the presence of PAI-1 mRNA in corneal lesions (data
not shown). No modification of the lymphatic vessel recruitment
was observed in the PAI-1
2/2 mice (n=5) compared to the wild
type mice (n=5) as assessed by the quantification of Lyve-1
labelled lymphatic vessels of the entire cornea (P=0.3064) (Fig. 5).
Structural features of the lymphatic network developed in the PAI-
1 WT or PAI-1
2/2 mice were also similar since all parameters
analysed by computerized image analysis were identical [26]: the
end-point density reflecting the number of vessels (P=0.2715), the
node density representing the number of branchings (P=0.4526)
and the length density corresponding the total length of the vessels
(P=0.3998).
Discussion
The plasminogen activation system is largely implicated in
pathological angiogenic processes. The genetic deficiency of PAI-1
in mice is associated to impaired blood vascularisation in several
experimental models [9,12,18] such as cancer [10,13] and
choroidal angiogenesis models [11,14]. The pivotal role of PAI-1
Figure 3. Primary tumor development and metastatic potential of PyMT mice crossed with PAI-1 WT or PAI-1
2/2 mice. Presented
results are from 11- and 14-week mice. (A): Tumor weight and (B): podoplanin positive relative surface in primary tumors observed in PAI-1 WT and
PAI-1
2/2 mice. (C): Percentage of metastasis in lymph nodes (black columns) and lungs (white columns). n=16 PAI-1 WT-PyMT and 17 PAI-1
2/2-PyMT
mice at 14 weeks, 17 PAI-1 WT-PyMT and 9 PAI-1
2/2-PyMT mice at 11 weeks. Data are 6 S.E.M. *P#0.05, NS=Non Significant.
doi:10.1371/journal.pone.0009653.g003
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protease inhibitor regulates also lymphangiogenesis. Surprisingly,
we previously reported that neither PAI-1 deficiency nor a
pharmacological inhibitor of serine proteases directly affect the
endothelial cell sprouting from thoracic duct explants in the
lymphatic ring assay [29]. Nevertheless, this finding does not
exclude a putative role of PAI-1 in vivo depending on the in vivo
microenvironment and for instance, on an inflammatory reaction
Figure 4. Development of lymphangioma in PAI-1 WT or PAI-1
2/2 mice. A macroscopic decrease of lymphangioma is observed in PAI-1
2/2
as compared to WT (A). Similar recruitment of lymphatic vessels (assessed by Lyve-1 positivity) (B), and of CD45 positive-inflammatory cells (C) was
observed in both genotypes. Evaluation of fibrosis was performed by Sirius red staining (D). Representative images are shown on the left and
quantifications performed by computerized image analysis are shown on the right Data are 6 S.E.M (n=6). Scale bars: A=0.5 mm, B–D=200 mm, **
P#0.01.
doi:10.1371/journal.pone.0009653.g004
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important issue, we applied to PAI-1 deficient mice two models of
breast cancer and two models of inflammation-related lymphan-
giogenesis. We found that PAI-1 is not essential for pathological
lymphangiogenesis.
We first used a orthotopic graft model of VEGF-C overex-
pressing-mammary carcinoma cells (MCF7). VEGF-C has been
indeed reported to promote tumor growth in SCID [22] and nude
mice [23]. Tumor lymphangiogenesis was increased in VEGF-C
MCF7 tumors injected in nude mice and lymph node metastasis
were found more frequently [23]. Similar results were reported
with VEGF-C overexpressing MDA-MB-435 [30]. In the present
study, MCF7 cells overexpressing or not VEGF-C were inoculated
into RAG-1
2/2 immunodeficient mice crossed with PAI-1 WT or
PAI-1 deficient mice. In accordance with previous reports [22,23],
we confirmed the increased growth rate of VEGF-C expressing
tumors. The pro-tumoral effect of VEGF-C was previously
attributed to a better oxygenation due to a slight angiogenic
response or a decreased intratumoral pressure because of the
increased number of lymphatic vessels. It is worth noting that the
mice background and the immunodeficiency rate are essential
factors influencing the lymph node dissemination. Indeed, the
propensity of VEGF-C expressing cells to disseminate into lymph
node was higher in nude mice [23,30] than in SCID mice [22] or
RAG-1
2/2 mice (the present study). Since these mice differ in
their B-lymphocyte status, it suggests that B lymphocytes might
contribute to lymph node dissemination of cancerous cells.
Accordingly, the requirement of B-lymphocytes was also observed
in a lymphangiogenesis model of mycoplasma infection of the
pulmonary tract [31].
In agreement with previous studies, PAI-1 deficiency was
associated with decreased tumor development [10,18]. We further
analysed the lymphatic invasion of these tumors and their
dissemination into lymph nodes. Although VEGF-C expression
led to an enhancement of lymphatic vessel numbers, no difference
was observed in PAI-1 WT and PAI-1
2/2 mice. Moreover, both
Figure 5. Photography and quantification of the Lyve-1 positive-network observed in the corneal assay in PAI-1 WT or PAI-1
2/2
mice. The node, end-point and length densities are presented for both experimental groups with a schematic illustration of each of these measured
parameters at the left. The area covered by the lymphatic vessels normalized to the total corneal area (relative surface, %) is also indicated. These
parameters quantified by computerized image analysis are defined in Material and Methods. Data are 6 S.E.M (n=5). Scale bar=400 mm, NS=Non
Significant.
doi:10.1371/journal.pone.0009653.g005
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data clearly demonstrate that PAI-1 is not implicated in tumoral
lymphangiogenesis. Moreover, our data are in line with a previous
study on PyMT transgenic mice showing that the primary tumor
growth was not significantly affected by PAI-1 deficiency and
neither was the lung metastatic burden [21]. We now demonstrate
that PAI-1 is dispensable for tumoral lymphangiogenesis by using
the PyMT and PAI-1 double transgenic mice.
Knowing that inflammation influences cancer progression
[32,33] and that lymphangiogenesis and inflammation processes
are closely related, we applied a model of lymphangioma to PAI-
1
2/2 mice. This system consists in a benign hyperplasia of
lymphatic vessels induced by the injection of Freund adjuvant and
is often used to isolate lymphatic endothelial cells [24,34]. In this
system, the inflammatory reaction induced by Freund adjuvant
relies on the recruitment of leukocytes by cytokines secreted by
cells of the peritoneum [35]. In PAI-1 deficient mice, we observed
a macroscopic decrease of the lymphangioma formation as
compared to PAI-1 WT mice. This effect could be ascribed to a
reduction of fibrosis rather than to a decrease in lymphatic vessel
recruitment. Accordingly, PAI-1 deficiency slowed down the
fibrotic reaction in different models [36,37] by accelerating
plasmin-mediated proteolysis [36] or by influencing macrophage
or myofibroblast recruitment [37]. The lack of PAI-1 effect on
inflammation related lymphangiogenesis was further confirmed by
similar injury-induced corneal lymphangiogenesis observed in
PAI-1
2/2 and PAI-1 WT mice. The increased lymphatic vessel
size observed in lymphangioma of PAI-1
2/2 mice is intriguing.
However, note that this variation in vessel structure is associated
with a reduction of matrix deposition which may influence vessel
branching. Studies on mammary gland morphogenesis revealed
that the collagen deposition inhibition reduced developing tubular
structure bifurcations [38]. The matrix proteolytic breakdown
could compromise the scaffold mechanical integrity necessary to
counter endothelial cells-generated forces during the tube
formation process [39,40]. Thus, the difference in vessel structure
likely relies on PAI-1-regulated fibrotic response rather than on a
direct effect of PAI-1 on lymphangiogenesis.
The present study using genetic approaches provide for the first
time evidences that in contrast to its pivotal role in pathological
angiogenesis, PAI-1 is dispensable in pathological lymphangiogen-
esis in tumoral situations as well as in inflammatory disorders. This
clearly demonstrates that distinct molecular pathways govern
angiogenesis and lymphangiogenesis and that PAI-1 plays distinct
roles in the remodelling of both circulation systems in pathological
conditions. Providing that PAI-1 antagonists are used to inhibit
angiogenesis [41], our results reveal that this approach will not
have any effect on lymphangiogenesis. Although PAI-1 is
dispensable for lymphangiogenesis, it is worth noting that other
proteolytic systems are mandatory for this process and particularly
matrix metalloproteases such as the MMP-2 whose deficiency
impairs lymphangiogenesis in in vitro and in vivo models [29].
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